Clinical applications of a peptide-based vaccine for glioblastoma

PMID: 19944970
Journal: Neurosurgery clinics of North America (volume: 21, issue: 1, Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-109)
Published: 2010-01-01

Authors:
Kanaly CW, Ding D, Heimberger AB, Sampson JH

ABSTRACT

Glioblastoma multiforme is a malignant, relentless brain cancer with no known cure, and standard therapies leave significant room for the development of better, more effective treatments. Immunotherapy is a promising approach to the treatment of solid tumors that directs the patient’s own immune system to destroy tumor cells. The most successful immunologically based cancer therapy to date involves the passive administration of monoclonal antibodies, but significant antitumor responses have also been generated with active vaccination strategies and cell-transfer therapies. This article summarizes the important components of the immune system, discusses the specific difficulty of immunologic privilege in the central nervous system, and reviews treatment approaches that are being attempted, with an emphasis on active immunotherapy using peptide vaccines.